| Market Cap | 10.72B | P/E | 15.73 | EPS this Y | 320.70% | Ern Qtrly Grth | 18.90% |
| Income | 663.9M | Forward P/E | - | EPS next Y | 9.80% | 50D Avg Chg | 4.00% |
| Sales | 3.44B | PEG | 0.54 | EPS past 5Y | - | 200D Avg Chg | 11.00% |
| Dividend | 4.00% | Price/Book | 3.06 | EPS next 5Y | 5.50% | 52W High Chg | -2.00% |
| Recommedations | - | Quick Ratio | 0.80 | Shares Outstanding | 330.84M | 52W Low Chg | 47.00% |
| Insider Own | - | ROA | 8.48% | Shares Float | 28.28M | Beta | 0.60 |
| Inst Own | 0.01% | ROE | 17.91% | Shares Shorted/Prior | -/- | Price | 31.45 |
| Gross Margin | 82.01% | Profit Margin | 19.83% | Avg. Volume | 583 | Target Price | - |
| Oper. Margin | 18.32% | Earnings Date | Jul 25 | Volume | 222 | Change | -0.47% |
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.